Yesterday, the Regulations Review Committee of the General Assembly approved a new condition for our state’s Medical Marijuana Program. The condition is Chronic Neuropathic Pain Associated with Degenerative Spinal Disorders.
The Committee also voted to update regulations to reschedule the medication Epidiolex (cannabidol) as a Schedule V medication. The Food and Drug Administration (FDA) approved the medication in June and the Drug Enforcement Administration (DEA) classified the medication as Schedule V in September. It is an oral solution used for some rare, severe types of seizure disorders.
“It’s always been important to us at DCP to make sure that patients get access to the medication they need as quickly as possible,” said Consumer Protection Commissioner Michelle H. Seagull, “These updates to the regulations mean that more patients with severe debilitating conditions will have additional options for medical treatment. I want to thank the members of the Board of Physicians for their thoughtful deliberation, and the members of the Regulations Review Committee for meeting with us quickly, and approving these changes to our regulations.”
The last step in this process is for DCP to submit the regulations to the Secretary of the State’s Office, who will post the regulations online. At that point, the regulations will be final.
There are currently 29,543 patients in Connecticut’s medical marijuana program, 1000 certifying physicians, and now a total of 31 conditions approved for adults and 8 for patients under 18. For more information about the medical marijuana program, please visit www.ct.gov/DCP/mmp. Questions or concerns can be emailed to firstname.lastname@example.org.
Source: Connecticut State Department of Consumer Protection – as featured in the Marijuana Moment newsletter